Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bing Z Carter

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Haematologica|February 2, 2023
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures <i>NPM1/FLT3</i>-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft modelBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood|August 16, 2003
Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosisBing Z Carter, Steven M Kornblau, Twee Tsao, et al.
Journal of the National Cancer Institute|August 3, 2006
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitorsBoglarka Gyurkocza, Janet Plescia, Christopher M Raskett, et al.
Cell Death & Disease|December 1, 2016
miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathwaysZhi Hong Fang, Si Li Wang, Jin Tao Zhao, et al.
Haematologica|December 23, 2020
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibitionBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Haematologica|August 3, 2019
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine modelBing Z Carter, Po Yee Mak, Hong Mu, et al.
International Journal of Biological Macromolecules|December 4, 2024
Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutationCamila Paz Quezada Meza, Valentina Salizzato, Elisabetta Calistri, et al.
Cell Death & Disease|July 24, 2020
Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathwayYuan-Fei Shi, Long Liu, Ling-Li He, et al.
Bone Marrow Transplantation|October 25, 2019
Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutationFang Chen, Junya Sun, Changxin Yin, et al.
Oncotarget|October 3, 2015
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Haematologica|February 2, 2023
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures <i>NPM1/FLT3</i>-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft modelBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood|August 16, 2003
Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosisBing Z Carter, Steven M Kornblau, Twee Tsao, et al.
Journal of the National Cancer Institute|August 3, 2006
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitorsBoglarka Gyurkocza, Janet Plescia, Christopher M Raskett, et al.
Cell Death & Disease|December 1, 2016
miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathwaysZhi Hong Fang, Si Li Wang, Jin Tao Zhao, et al.
Haematologica|December 23, 2020
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibitionBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Haematologica|August 3, 2019
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine modelBing Z Carter, Po Yee Mak, Hong Mu, et al.
International Journal of Biological Macromolecules|December 4, 2024
Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutationCamila Paz Quezada Meza, Valentina Salizzato, Elisabetta Calistri, et al.
Cell Death & Disease|July 24, 2020
Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathwayYuan-Fei Shi, Long Liu, Ling-Li He, et al.
Bone Marrow Transplantation|October 25, 2019
Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutationFang Chen, Junya Sun, Changxin Yin, et al.
Oncotarget|October 3, 2015
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cellsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Pageof 8